Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1988 Mar;85(5):1620–1623. doi: 10.1073/pnas.85.5.1620

A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection.

J W van der Meer 1, M Barza 1, S M Wolff 1, C A Dinarello 1
PMCID: PMC279825  PMID: 3125553

Abstract

Natural and synthetic immunomodulators that increase nonspecific resistance to infection induce interleukin 1 (IL-1) production. Therefore, we investigated the effect of the administration of IL-1 on the survival of lethally infected granulocytopenic mice. Mice with cyclophosphamide-induced granulocytopenia were injected with approximately 10(7) Pseudomonas aeruginosa in the thigh muscle at time 0; gentamicin was administered 6 hr and 23 hr later. When recombinant human IL-1 beta (one of the two forms of IL-1) was given as a single i.p. injection 24 hr before the infection, survival was increased. Using 80 ng of IL-1 beta per mouse, survival compared to control animals was 98% vs. 71% at 24 hr, 98% vs. 60% at 30 hr, 86% vs. 36% at 36 hr, and 61% vs. 11% at 48 hr (P less than 0.001) after the infection. No effect of IL-1 was observed when it was given 0.5 hr before or 6 hr after the infection. Animals not treated with gentamicin also benefited from the IL-1. Administration of the cyclooxygenase inhibitor ibuprofen did not affect the activity of IL-1. Numbers of bacteria cultured from the blood, thigh muscle, liver, spleen, and kidney were similar in IL-1-treated and control animals. Superoxide production by peritoneal macrophages was also similar in the two groups. These studies demonstrate that IL-1 pretreatment protects granulocytopenic mice against lethal pseudomonas infection and suggest that this protection occurs through a noncellular mechanism.

Full text

PDF
1620

Images in this article

1622Image
on p.1622

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Buckley M., Sathe Y. S., Freireich E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 Feb;64(2):328–340. doi: 10.7326/0003-4819-64-2-328. [DOI] [PubMed] [Google Scholar]
  2. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chong K. T. Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. Infect Immun. 1987 Mar;55(3):668–673. doi: 10.1128/iai.55.3.668-673.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cluff L. E. Effects of endotoxins on susceptibility to infections. J Infect Dis. 1970 Sep;122(3):205–215. doi: 10.1093/infdis/122.3.205. [DOI] [PubMed] [Google Scholar]
  5. Cummings N. P., Pabst M. J., Johnston R. B., Jr Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide. J Exp Med. 1980 Dec 1;152(6):1659–1669. doi: 10.1084/jem.152.6.1659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dinarello C. A., Cannon J. G., Mier J. W., Bernheim H. A., LoPreste G., Lynn D. L., Love R. N., Webb A. C., Auron P. E., Reuben R. C. Multiple biological activities of human recombinant interleukin 1. J Clin Invest. 1986 Jun;77(6):1734–1739. doi: 10.1172/JCI112495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dinarello C. A. Interleukin-1. Rev Infect Dis. 1984 Jan-Feb;6(1):51–95. doi: 10.1093/clinids/6.1.51. [DOI] [PubMed] [Google Scholar]
  8. Elin R. J., Wolff S. M. The role of iron in nonspecific resistance to infection induced by endotoxin. J Immunol. 1974 Feb;112(2):737–745. [PubMed] [Google Scholar]
  9. Gerber A. U., Craig W. A., Brugger H. P., Feller C., Vastola A. P., Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis. 1983 May;147(5):910–917. doi: 10.1093/infdis/147.5.910. [DOI] [PubMed] [Google Scholar]
  10. Kampschmidt R. F., Pulliam L. A. Stimulation of antimicrobial activity in the rat with leukocytic endogenous mediator. J Reticuloendothel Soc. 1975 Mar;17(3):162–169. [PubMed] [Google Scholar]
  11. Kimball H. R., Williams T. W., Wolff S. M. Effect of bacterial endotoxin on experimental fungal infections. J Immunol. 1968 Jan;100(1):24–33. [PubMed] [Google Scholar]
  12. Kunst M. W., Mattie H., van Furth R. Antibacterial efficacy of cefazolin and cephradine in neutropenic mice. Infection. 1979;7(1):30–34. doi: 10.1007/BF01640554. [DOI] [PubMed] [Google Scholar]
  13. Lisi P. J., Chu C. W., Koch G. A., Endres S., Lonnemann G., Dinarello C. A. Development and use of a radioimmunoassay for human interleukin-1 beta. Lymphokine Res. 1987 Summer;6(3):229–244. [PubMed] [Google Scholar]
  14. Mochizuki D. Y., Eisenman J. R., Conlon P. J., Larsen A. D., Tushinski R. J. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5267–5271. doi: 10.1073/pnas.84.15.5267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Neta R., Douches S., Oppenheim J. J. Interleukin 1 is a radioprotector. J Immunol. 1986 Apr 1;136(7):2483–2485. [PubMed] [Google Scholar]
  16. Ozaki Y., Ohashi T., Minami A., Nakamura S. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a. Infect Immun. 1987 Jun;55(6):1436–1440. doi: 10.1128/iai.55.6.1436-1440.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pabst M. J., Johnston R. B., Jr Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J Exp Med. 1980 Jan 1;151(1):101–114. doi: 10.1084/jem.151.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Parant M., Riveau G., Parant F., Dinarello C. A., Wolff S. M., Chedid L. Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. J Infect Dis. 1980 Nov;142(5):708–715. doi: 10.1093/infdis/142.5.708. [DOI] [PubMed] [Google Scholar]
  19. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Riveau G. R., Novitsky T. J., Roslansky P. F., Dinarello C. A., Warren H. S. Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide. J Clin Microbiol. 1987 May;25(5):889–892. doi: 10.1128/jcm.25.5.889-892.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shenep J. L., Mogan K. A. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1984 Sep;150(3):380–388. doi: 10.1093/infdis/150.3.380. [DOI] [PubMed] [Google Scholar]
  22. Weyand C., Goronzy J., Fathman C. G., O'Hanley P. Administration in vivo of recombinant interleukin 2 protects mice against septic death. J Clin Invest. 1987 Jun;79(6):1756–1763. doi: 10.1172/JCI113016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. White C. W., Ghezzi P., Dinarello C. A., Caldwell S. A., McMurtry I. F., Repine J. E. Recombinant tumor necrosis factor/cachectin and interleukin 1 pretreatment decreases lung oxidized glutathione accumulation, lung injury, and mortality in rats exposed to hyperoxia. J Clin Invest. 1987 Jun;79(6):1868–1873. doi: 10.1172/JCI113029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wright L. J., Kimball H. R., Wolff S. M. Alterations in host responses to experimental Candida albicans infections by bacterial endotoxin. J Immunol. 1969 Dec;103(6):1276–1282. [PubMed] [Google Scholar]
  25. van Furth R., Cohn Z. A. The origin and kinetics of mononuclear phagocytes. J Exp Med. 1968 Sep 1;128(3):415–435. doi: 10.1084/jem.128.3.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. van der Meer J. W., Alleman M., Boekhout M. Infectious episodes in severely granulocytopenic patients. Infection. 1979;7(4):171–175. doi: 10.1007/BF01640936. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES